[Featured Stock] Dragonfly Soars to Upper Limit on Expectations for Commercialization of Digital Therapeutic Devices

Dragonfly is recording a limit-up. The news that the digital therapeutic device ‘Guardians DTx’ was selected for the Ministry of Health and Welfare’s research and development project appears to have had an impact.

As of 9:39 AM on the 22nd, Dragonfly was trading at 646 KRW, up 149 KRW (29.98%) compared to the previous trading day.

Dragonfly announced on the same day that it was selected for the ‘Medical Institution-Based Digital Healthcare Demonstration and Adoption’ project under the ‘2023 2nd Health and Medical Technology R&D Project’ led by the Ministry of Health and Welfare, in order to focus on the commercialization of game-type digital therapeutic devices. Starting this year, it will receive approximately 1.7 billion KRW in government support over three years to conduct clinical demonstration and commercialization of the game-type digital therapeutic device ‘Guardians DTx’ (tentative name).

The 2nd Health and Medical Technology R&D Project is conducted as part of the government’s 3rd Basic Plan for Health and Medical Technology Promotion. The government supports the development of next-generation promising biohealth technologies such as digital therapeutic devices with the goal of ‘realizing a Healthcare 4.0 era where all citizens are healthy.’

Dragonfly, which has identified digital therapeutic devices as a new business, developed Guardians DTx to help treat ADHD (Attention Deficit Hyperactivity Disorder) in children aged 7 to under 13. Currently, exploratory clinical trials targeting pediatric patients are underway in collaboration with Pusan National University Hospital and the Industry-Academic Cooperation Foundation of Pusan National University.

This content was produced with the assistance of AI translation services.